Last Updated on October 15, 2024 by The Health Master
Unichem Laboratories has received ANDA approval for its ranolazine extended-release tablets, 500 mg and 1000 mg from the United States Food and Drug Administration (USFDA).
This drug approval is to market a generic version of Ranexa (ranolazine extended-release tablets) 500 mg and 1000 mg, of Gilead Sciences.
Ranolazine Extended-Release Tablets, 500 mg, and 1000 mg are indicated for the treatment of chronic angina.
The product will be commercialised from Unichem’s Goa Plant.
USFDA gives nod for Human Trial of drug for the treatment of advanced cancer
USFDA gives approval for Clindamycin Hydrochloride Capsules
USFDA gives nod for generic version of Famotidine tablets
USFDA gives approval for Lenalidomide capsules
USFDA approves Nasal spray for opioid overdose
USFDA gives final approval for Prazosin Hydrochloride capsules
Drug recall: Brimonidine Tartrate Ophthalmic Solution recalled due to this reason
Spurious drugs worth Rs 5 Lakh seized: UP
How to prepare SOPs in the Pharma Industry
NMC rejects proposal to allow Pharmacists to write Prescriptions
SC: Doctor can’t be punished under D&C Act for storing small quantities of medicines
Delhi High Court asks Centre to file status report on sale medicines online
Govt amends New Drugs and Clinical Trials Rules, 2019
Guidelines on medical negligence under consideration
Difference between branded and generic medicines
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
